Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder in women of reproductive age. PCOS is associated with multiple comorbidities including, obesity, insulin resistance and type 2 diabetes, as well as mood disorders and impaired quality of life (QoL). Obstructive sleep apnoea (OSA) is also a common medical condition that is often undiagnosed, particularly in women. OSA is associated with a similar spectrum of comorbidities to that observed in PCOS, including manifestations of the metabolic syndrome and impaired QoL, whilst obesity frequently constitutes a common denominator in the pathophysiology of both OSA and PCOS. Hence, it is not surprising that OSA and PCOS may coexist in women of reproductive age, and the current clinical guidelines on the management of PCOS recommend screening for OSA symptoms in overweight/obese women with PCOS. In this review, we examine the relationship between OSA and PCOS and explore the potential underlying mechanisms that link these two conditions.
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| INTRODUCTION
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age with a prevalence of 6%-15%.
1,2
PCOS is associated with obesity, subfertility, insulin resistance (IR) and type 2 diabetes (T2DM), depression and impaired quality of life (QoL). 3, 4 However, despite its high prevalence and significant comorbidities, our understanding of its underlying pathophysiology remains poor; with limited treatment options available to manage this lifelong disorder in everyday clinical practice. Hence, there is a need to improve the understanding of the pathogenesis of PCOS, and the spectrum of factors that might contribute to the clinical manifestations and comorbidities of this very common condition.
Obstructive sleep apnoea (OSA) is also an obesity-related disorder.
OSA prevalence in the general population is estimated at 17%-26% in men and 9%-28% in women, but this difference varies depending on the definition and methods used to diagnose OSA. 5 OSA is characterized by recurrent episodes of partial (hypopnoea) or complete (apnoea)
upper airway obstructions associated with recurrent oxygen desaturations and cyclical changes in heart rate, blood pressure, intrathoracic pressure and sympathetic activity. 6 In addition, OSA results in changes in the sleep architecture, including loss of deep sleep (stages 3 and 4) and/or of REM sleep.
6
Patients with OSA may present with nocturnal symptoms, including snoring, witnessed apnoea episodes, choking or gasping, insomnia, nocturia, enuresis, frequent arousals, diaphoresis and impotence. Despite the high prevalence of OSA in the general population, this condition is generally under-recognized and frequently remains undiagnosed in everyday clinical practice, particularly in women who may not present with typical OSA symptoms. 10 As obesity is a common risk factor, it is not surprising that OSA and PCOS might coexist.
The association between PCOS and OSA has also been recognized in the latest guidelines by the European and the US Endocrine Societies (Box 1). 3, 11 However, these guidelines acknowledge the limited evidence behind their recommendations that is largely based on limited, "weak," or "low quality" data. This highlights the need for further research to better understand the relationship between PCOS and OSA. In addition, the implications of OSA in women with PCOS are not clear, although important as both conditions are associated with overlapping comorbidities, and OSA is associated with essential factors that may contribute to the burden of PCOS (eg to IR, increased inflammation and oxidative stress). 5, 12 In this article, we present a concise review of key studies that examined the relationship between OSA and PCOS, and we explore the potential mechanisms linking both conditions.
| METHODOLOGY
We conducted a narrative review of the relevant literature. In this context, we searched PubMed using the terms "(PCOS OR polycystic ovary syndrome) AND (OSA OR obstructive sleep apnoea OR obstructive sleep apnea)." Clinical studies and review articles examining the presence of OSA in women with PCOS were obtained, reviewed, and their results were critically appraised. We also handsearched references from relevant papers and review articles.
| EPIDEMIOLOGY

| PCOS prevalence in OSA
Polycystic ovary syndrome has a prevalence of 6%-15% in women of reproductive age
1
; however, the reported prevalence rates vary depending on the populations studied and the applied PCOS diagnostic criteria.
The prevalence of PCOS in women with OSA remains unknown.
| OSA prevalence in PCOS
The prevalence of OSA in the general population varies considerably between studies, mainly due to differences in the populations studied, study designs and the methods and criteria used to diagnose OSA. 7 The prevalence of three well-conducted studies with similar designs from the USA (Wisconsin and Pennsylvania), and Spain showed an OSA prevalence of 9%-28% in women, with 2%-7% for moderate-to-severe OSA.
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To date, a limited number of studies have examined the prevalence of OSA in women with PCOS with the majority of these being conducted in the USA. Based on the existing published studies [14] [15] [16] [17] [18] [19] [20] [21] [22] ( and another showing 0/22 (0%) prevalence. 19 Based on the available data on the prevalence and natural history of these two conditions, it is probable that PCOS precedes the development of OSA; however, it cannot be excluded that OSA may precede the clinical presentation of PCOS in some women, worsening the PCOS-related symptomatology.
BOX 1 Clinical guidelines/recommendations on screening women with PCOS for OSA
• Endocrine Society, 2013
We suggest screening overweight/obese adolescents and women with PCOS for symptoms suggestive of OSA and, when identified, obtaining a definitive diagnosis using polysomnography. If OSA is diagnosed, patients should be referred for institution of appropriate treatment.
• European Society of Endocrinology, 2014
:
It seems wise at this moment to screen sleep disorders by clinical questionnaires in obese women with PCOS. In the case of clinical suspicion resulting from these questionnaires, patients should be referred to a centre of sleep disorders for polysomnography and further evaluation.
Observational long-term studies are needed to accurately assess the incidence of OSA in women with PCOS and vice versa.
| PROPOSED MECHANISMS LINKING OSA TO PCOS AND ITS COMORBIDITIES
Depending on ethnicity and geography, 30%-88% of women with PCOS are overweight or obese. 23 Obesity may contribute to the development of PCOS through increased android (central) type adiposity and IR
24
; lipotoxicity
25
; and increased 5α-reductase activity. 23 Obesity is also a major risk factor for OSA. 7 The mechanisms that link obesity to OSA are multifactorial. 
7,26
Subsequently, obesity is a key factor that predisposes to both PCOS and OSA. However, other shared features between PCOS and OSA may also play an important mechanistic role in the development/interaction between these two common conditions.
| Sex Hormones
An increase in circulating androgens of ovarian origin is one of the main features of PCOS and is present in both ovulatory and anovulatory women. Androgens cause many of the clinical features of PCOS (eg hirsutism, acne and alopecia); contribute to anovulation by promoting ovarian early follicular growth and subsequently disrupt follicular development and dominant follicle selection
27
; and exacerbate IR. Anovulation will result in lower progesterone levels.
Hyperandrogensim and low progesterone levels may play a role in the pathogenesis of OSA by increasing upper airway collapsibility, and/or impairing the sensitivity and responsiveness of the ventilatory chemoreceptors. 28 However, the effect of hyperandrogenism on OSA risk in women with PCOS is probably small, as androgen levels are relatively low compared to men. Sleep, on the other hand, appears to have a significant effect on the female hormone production. 
| Insulin resistance
Insulin resistance is seen in more than 50% of women with PCOS, independent of obesity. 32 Insulin may act directly on the ovaries to T A B L E 1 Differences between women with PCOS and OSA compared to women with PCOS only enhance androgen production
33
; reduces SHBG production from the liver with subsequent increase in bioavailable testosterone; and causes the premature arrest of follicle growth and anovulation.
34
Most studies also suggest an association between OSA and IR
7
; studies in healthy lean men found OSA to be associated with IR even in the absence of obesity. 35 In addition, in a cohort study, OSA, apnoea/ hypopnea index (AHI), oxygen desaturation index (ODI) and minimal oxygen saturations were independently associated with IR development over an 11-year follow-up period after adjustment for age, baseline BMI, BMI change over follow-up, hypertension and CPAP treatment. 36 Two recent meta-analyses showed that CPAP treatment was associated with a reduction in the homeostasis model assessment of insulin resistance (HOMA-IR), 37, 38 although this benefit may occur only in those using CPAP >4 hours per night. 39 Subsequently, it is plausible that OSA, through IR, may contribute to the development of a more severe PCOS phenotype in women affected by both conditions; or to a de novo presentation of PCOS in genetically/metabolically predisposed women.
| Oxidative stress
In a recent systematic review and meta-analysis, PCOS was associated with increased levels of oxidative stress, independent of age and BMI. 40 Oxidative stress may play a role in the pathogenesis of 
| Endothelial dysfunction
Women with PCOS have been found to have lower flow-mediated dilatation (FMD) compared to age-and weight-matched controls.
44
Obesity, IR, oxidative stress, advanced glycation end-products (AGE) and inflammation are believed to play a role in the pathogenesis of endothelial dysfunction in PCOS. 45 OSA is also associated with endothelial dysfunction, and the underlying mechanisms are likely related to ischaemia-reperfusion injury. 46 Repetitive episodes of re-oxygenation after hypoxaemia in patients with OSA result in increased production of AGE and ROS; 43 altered protein kinase C signalling; decreased endothelial nitric oxide synthase
47
; increased endothelin-1 levels and inflammation. 48 Notably, CPAP treatment was found to increase FMD in patients with OSA. contribute to the activation of the sympathetic nervous system (SNS).
| Sympathetic activity
Moreover, treatment with CPAP is associated with a reduction in sympathetic activity. 
| THE IMPACT OF OSA IN WOMEN WITH PCOS
| Review of published studies
A limited number of studies have examined the effect(s) of OSA in women with PCOS, and their findings are summarized in Table 1 .
In the study by Vgontzas et al., 15 women with PCOS and sleep disordered breathing (SDB was defined as either OSA or upper airway resistance syndrome; n=9) were heavier (BMI 45.7±2.6 vs. showed that insulin levels and glucose-to-insulin ratio had a stronger association with SDB than age, BMI or testosterone levels. However, the difference in BMI between the two groups in this study was rather high (8.5 kg/m 2 ), and despite statistical adjustment, it is difficult to completely rule out an effect of obesity on the metabolic differences between the two groups.
Similarly, in the study by Tasali However, this study lacked a control group, and only a "per protocol"
analysis was performed including just nine study participants, with the data from another 10 study patients being excluded from the analysis due to lack of adequate CPAP treatment compliance (average use of CPAP <4 hours per night). Of note, whether the reported posttreatment changes in IR and blood pressure observed in this study may translate/result into meaningful clinical outcomes remain to be studied.
In another study by 
| Summary of the literature
It seems plausible that OSA is associated with the severity of the PCOS phenotype, particularly in overweight/obese and insulin resistant women with PCOS. However, it is difficult to draw firm conclusions from the studies conducted so far since significant variables (eg abdominal adiposity and ethnicity) have often not been accounted for in the presented analyses. In addition, whilst the association between OSA and increased insulin resistance in women with PCOS seems to be a common theme, the relationship between OSA and hyperandrogenism is more controversial and require further evaluation. Whilst the US and European Endocrine societies' guidelines consider the presence of OSA as a cardiovascular risk factor in women with PCOS, 3, 11 there is lack of data on the exact relationship between OSA and important clinical outcomes in women with PCOS (eg on T2DM risk, cardiovascular risk, subfertility, depression and impaired QoL). Subsequently, well-conducted observational studies are needed to examine the effects of OSA in women with PCOS.
Interventional studies are also required in women with PCOS and OSA. The existing short-term, pilot, interventional study in such patients suggests that CPAP therapy may significantly improve insulin sensitivity and reduce blood pressure. However, it remains unclear whether this can translate into long-term meaningful clinical outcomes. 
| CONCLUSIONS
Obstructive sleep apnoea appears to be common in obese women with PCOS. There is a lack of high-quality evidence regarding the clinical benefit or the cost-effectiveness of the current Endocrine Society clinical practice guidelines which suggest screening all overweight/ obese adolescents and women with PCOS for symptoms suggestive of OSA. Whilst it is probable that PCOS precedes and contributes to the development of OSA, it is also plausible that OSA may contribute to the presentation and worsen the clinical manifestations of PCOS. Both conditions are associated with significant comorbidities in women (eg depression, unexplained fatigue, hypertension, dyslipidaemia, IR and impaired glucose tolerance) and may progress undiagnosed for prolonged periods. In order to inform clinical practice and support evidence-based guidelines, further clinical research is needed, including prospective cohort studies in obese and nonobese women with PCOS, to study in detail the relationship between these two important and prevalent conditions.
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